Dr Priscilla Brastianos, page-105

Another meeting cancelled due to COVID-19.
: PI3-Kinase and PTEN at the Interface of Cell Growth, Vesicular Trafficking and Disease (E1)
May 3-7, 2020 • Herrenhausen Palace • Hannover, Germany
https://tks.keystonesymposia.org/index.cfm?e=Web.Meeting.Flyer&MeetingID=1682

IMO Genentech will soon agree to a Paxalisib partnership deal with Kazia with a good outcome for both companies.
The fact that Dr P Brastianos recommended GDC-0084 over other PI3K inhibitors for the ALLIANCE trial, says it all.
Genentech will seal the deal well before the ALLIANCE trial researchers get over excited.
Kazia shareholders are extremely fortunate to have the licence for such a valuable drug that is a dual PI3K / mTOR inhibitor that works and improves the patient's lives, plus it can cross the blood brain barrier.
It would not surprise me for Genentech to buy Paxalisib back!

Regards.